Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) EBT (2020 - 2025)

Xeris Biopharma Holdings' EBT history spans 6 years, with the latest figure at $11.1 million for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 316.72% year-over-year to $11.1 million, compared with a TTM value of $554000.0 through Dec 2025, up 100.97%, and an annual FY2025 reading of $554000.0, up 100.97% over the prior year.
  • EBT for Q4 2025 was $11.1 million at Xeris Biopharma Holdings, up from $621000.0 in the prior quarter.
  • The five-year high for EBT was $11.1 million in Q4 2025, with the low at -$50.8 million in Q4 2021.
  • Average EBT over 5 years is -$16.9 million, with a median of -$17.6 million recorded in 2021.
  • Year-over-year, EBT crashed 132.37% in 2021 and then skyrocketed 316.72% in 2025.
  • Tracing XERS's EBT over 5 years: stood at -$50.8 million in 2021, then surged by 73.88% to -$13.3 million in 2022, then decreased by 2.7% to -$13.6 million in 2023, then skyrocketed by 62.48% to -$5.1 million in 2024, then skyrocketed by 316.72% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's EBT are $11.1 million (Q4 2025), $621000.0 (Q3 2025), and -$1.9 million (Q2 2025).